Serum asymmetric dimethylarginine levels in diabetic patients with neuropathy

Diabetes Research and Clinical Practice

Volumn 92, Issue 2, 2011, Pages 223-227

  Yaşar, Halit ^a   Şenol, Mehmet Güney ^a   Kendirli, Tansel ^a   Önem, Yalçin ^a   Özdaĝ, Fatih ^a   Saraçoĝlu, Mehmet ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Asymmetric dimethylarginine; Diabetes mellitus; Diabetic neuropathy; Retinopathy

Indexed keywords

HEMOGLOBIN A1C; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ARTICLE; ASYMMETRIC DIMETHYLARGININE BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MOUSE; NERVE CONDUCTION; NEUROPATHY SYMPTOM SCORE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; DIABETIC NEUROPATHIES; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 79955823414     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.01.015     Document Type: Article

References (20)

1. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002, 51:843-846.
2. Abbasi F., Asagmi T., Cooke J.P., Lamendola C., McLaughlin T., Reaven G.M., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88:1201-1203.
3. Lu T.M., Ding Y.A., Leu H.B., Yin W.H., Sheu W.H., Chu K.M., et al. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004, 94:157-161.
4. Chan N.N., Chan J.C. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 2002, 45:1609-1616.
5. Yoo J.H., Lee S.C. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001, 158:425-430.
6. Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M., et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy study. Neurology 1993, 43:817-824.
7. Thomas P.K, Tomlinson D.R. Neuropathy associated with systemic disease. Peripheral Neuropathy 1993, Saunders Company, Mexico, p. 1219-41.
8. Dyck P.J. Detection, characterization and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1998, 11:21-32.
9. Stuhlinger M.C, Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420-1426.
10. Wakino S., Hayashi K., Tatematsu S., Hasegawa K., Takamatsu I., Kanda T., et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005, 28:255-262.
11. Lawrence E., Brain S.D. Altered microvascular reactivity to endothelin-1, endothelin-3 and NG-nitro-L-arginine methylester in streptozotocin-induced diabetes mellitus. Br J Pharmacol 1992, 106:1035-1040.
12. Mittermayer F., Mayer B.X., Meyer A., Winzer C., Pacini G., Wagner O.F., et al. Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabetologia 2002, 45:1372-1378.
13. Eid H.M., Eritsland J., Larsen J., Arnesen H., Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease: effects of pravastatin. Atherosclerosis 2003, 166:279-284.
14. Xiong Y., Lei M., Fu S., Fu Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes. Life Sci 2005, 77:149-159.
15. Sugai M., Ohta A., Ogata Y., Nakanishi M., Ueno S., Kawata T., et al. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J 2007, 54:303-339.
16. Devangelio E., Santilli F., Formoso G., Ferroni P., Bucciarelli L., Michetti N., et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007, 43:511-518.
17. Päivä H., Lehtimäki T., Laakso J., Ruokonen I., Rantalaiho V., Wirta O., et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003, 52:303-307.
18. Abhary S., Kasmeridis N., Burdon K.P., Kuot A., Whiting M.J., Yew W.P., et al. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines. Diabetes Care 2009, 32:2084-2086.
19. Yonem A., Duran C., Unal M., Ipcioglu O.M., Ozcan O. Plasma apelin and asymmetric dimethylarginine levels in type 2 diabetic patients with diabetic retinopathy. Diabetes Res Clin Pract 2009, 84:219-223.
20. Senol M.G., Saracoglu M. Significance of neuropathy symptom and disability scores in the diagnosis of neuropathy in Turkish diabetic patients. Neurol Psychiatry Brain Res 2007, 14:45-50.